NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the U.S. FDA has accepted its New Drug Application to review its investigational product candidate, NGX-4010, for the management of pain due to post-herpetic neuralgia.
the details can be read here.
No comments:
Post a Comment